Combe announces launch of Preventeza Emergency Contraceptive and campaign

-

As current technologies are advancing more in finding out solutions for health problems, they are marching forward with little steps starting from prevention to cure.One such kind of prevention for unplanned pregnancies and to avoid certain complicated pregnancies Vagisil have announced  a newer method for prevention weeks before. 
Combe Inc., the makers of Vagisil®,announced the launch of its Preventeza Emergency Contraceptive (levonorgestrel tablet, 1.5 mg)  to showcase solidarity around women's reproductive rights. To demonstrate its commitment to helping women learn more about emergency contraception (EC), the Company is planning to give away up to $1 million worth of free product via the launch of its "Buy One Get One or Give One (BoGoGo)" product campaign where women who purchase Preventeza on Vagisil.com will have the option to get a second one for free to either keep on hand or to give to another woman in their life.
New Preventeza by Vagisil, available online or over-the-counter (OTC) as a single tablet, takes the panic out of a stressful moment, and is a proven option to help women prevent pregnancy before it starts by using the same ingredient as most birth control pills, just at a higher dose. By keeping Preventeza on hand, women can always be prepared and in control.
BoGoGo promotion  provides  with the opportunity to educate women about the need for and the importance of access to emergency contraception (EC). Moreover, it remains shocking  that while 1 in 2 women may need an EC in their lifetime, only 10 percent of women have actually used it, said Keech Combe Shetty, CEO of Vagisil. This is why we are giving away up to $1 million worth of Preventeza as it aligns with our mission at Vagisil to empower women to take ownership of their reproductive health without shame."
Preventeza's BoGoGo promotion is available nationwide and can be activated at checkout online at Vagisil.com. In parallel, the Company is launching the #WeAre1in2 campaign on social media that is aimed at increasing awareness of the fact that 1 in 2 women may need EC in their lifetime due to the risk of unintended pregnancies. People are encouraged to showcase their solidarity using #WeAre1in2 on social media.
Preventeza is brought to you by the makers of Vagisil, a trusted women's health brand, that encourages women to talk about health topics they are uncomfortable discussing, provides facts and resources to help educate, and thereby reduces the shame that still exists around vaginal and sexual health."It is an important time in the history of our country for women to gather together on critical issues related to reproductive health. The fact that 45 percent of pregnancies remain unplanned or mistimed clearly demonstrates the need for education so women can understand that there are safe and effective tools that serve as back-ups for regular birth control in case of unprotected sex or when birth control fails. In addition to practicing safe sex, there are EC options, such as Vagisil's Preventeza, available to all women of reproductive age," said Logan Levkoff, PhD, MS, an internationally recognized expert on sexuality and relationships. "I am proud that Preventeza is launching a dialogue on this timely movement that will help to differentiate myths versus facts about EC while increasing access for all women."

How Preventeza Works
Preventeza can be taken within 72 hours (three days) after unprotected sex has occurred, yet is most effective the sooner it is taken. Preventeza works mainly by stopping the release of an egg from the ovary. Preventeza will not harm an existing pregnancy. Preventeza does not protect women from HIV infection (the virus that causes AIDS) and other sexually transmitted diseases (STDs).
When used as directed, Preventeza can significantly decrease the chance of a woman becoming pregnant after unprotected sex. Approximately seven out of every eight women who would have become pregnant will not after taking Preventeza.
Reference: https://www.news-medical.net/news/20180706/Combe-announces-launch-of-Preventeza-Emergency-Contraceptive-and-campaign.aspx

Comments

Post a Comment

Popular posts from this blog

People living with HIV underestimate the harm of smoking

-
Image
People with HIV in Denmark who smoke greatly underestimate the impact of smoking on life expectancy, a study of perceptions of life expectancy published this month in the  Journal of Acquired Immune Deficiency Syndromes   shows. Current smokers living with HIV, asked to estimate their life expectancy, anticipated their life expectancy to be 3.65 years lower than people with HIV who had never smoked. However, epidemiological research carried out in Denmark indicates that smoking reduces life expectancy by 12 years in people living with HIV. In comparison, the overall estimation of life expectancy by people living with HIV was accurate.  Danish research estimates that HIV infection will reduce life expectancy by five years  compared to the general population. People living with HIV perceived their life expectancy to be almost four-and-a-half years shorter (4.26 years) than people in the general population asked to estimate their life expectancy. The study was carried out by researc
Read more

Trial of ‘kick and kill’ approach to HIV cure leaves puzzles to be solved

-
Image
Researchers have reported the results of the first randomized clinical trial to test a novel strategy. The approach involves waking up and then killing the ‘sleeping’ HIV that is hiding in the body using an experimental approach known as ‘kick and kill’. Led by  Imperial College London , the  University of Oxford ,  MRC Clinical Trials Unit at UCL , and the  University of Cambridge , the RIVER study aimed to improve on current care by eradicating HIV from the body, which would represent a major step forward in the search for a cure. The RIVER study, which ran from 2015 to 2018 in London and Brighton, tested the ‘kick and kill’ approach in 60 men recently diagnosed with HIV and who had the virus under control by taking ART. Although investigators found no difference in effect between those participants who received the active ‘kick and kill’ therapy and those who had standard treatment, they say the trial paves the way for testing different combinations of therapies to tac
Read more

New born syphilis on the rise sparking concerns

-
Image
Congenital syphilis or new born syphilis occurs in the new born baby when the mother is affected with the syphilis bacteria during pregnancy or delivery and passes it on to her baby. A  new report  that was released this Tuesday (25th September 2018) by the US Centers for Disease Control and Prevention (CDC) that showed that in the US, the numbers of these new born syphilis cases have doubled since 2013. According to the CDC report, the infection is passed on to the baby in 80 percent of cases where the mother is infected. This can cause death or still birth in the baby in nearly 40 percent of the pregnancies. The report states that in 2013 the number of cases were 362 that jumped to 918 in 2017. Nearly 7 in 10 of these cases come from five states - Arizona, California, Florida, Louisiana and Texas. Louisiana leaded the rest with 93.4 cases for every 100,000 births. Western and Southern states are most commonly affected among the 32 states from where reports have emerge
Read more